Boston Partners
YMAB

Boston Partners’s Y-mAbs Therapeutics YMAB Stock Holding History

Boston Partners’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,165
Closed -$556K – 803
2024
Q1 		$556K Buy
+34,165
New +$460K ﹤0.01% 679

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Boston Partners's YMAB Position: Q2 2024 in Review

Boston Partners sold out of Y-mAbs Therapeutics (YMAB) in Q2 2024, closing a stake of 34,165 shares — an estimated $556K sold.

Boston Partners first reported a position in YMAB in Q1 2024 and held it in 1 quarter. The position peaked at $556K in Q1 2024. 96 funds tracked by Wall St. Rank hold YMAB as of Q2 2024.

  • Boston Partners reported no remaining Y-mAbs Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Boston Partners sold 34,165 Y-mAbs Therapeutics shares in Q2 2024, an estimated $556K.
  • Boston Partners first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 1 quarter.
  • Boston Partners's Y-mAbs Therapeutics position peaked at $556K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2024.

Based on Boston Partners's 13F filing for Q2 2024, filed 14 Aug 2024.